Variables | Patients with ILD (n = 102) | Patients without ILD (n = 247) | p-value |
Age (years) | 69.9 ± 9.7 | 61.0 ± 12.9 | <0.001 |
Gender (M/F) | 55/47 | 110/137 | 0.110 |
MPO-positive AAV | 99 (97.1%) | 217 (87.9%) | 0.008 |
PR3-positive AAV | 3 (2.9%) | 30 (12.2%) |
|
General manifestation | 69 (67.7%) | 173 (70.0%) | 0.659 |
Skin involvement | 3 (2.9%) | 19 (7.7%) | 0.097 |
ENT involvement | 5 (4.9%) | 10 (4.1%) | 0.946 |
Cardiovascular involvement | 25 (24.5%) | 87 (35.2%) | 0.051 |
Abdominal involvement | 27 (26.5%) | 73 (29.6%) | 0.562 |
Nervous system involvement | 11 (10.8%) | 28 (11.3%) | 0.882 |
Kidney involvement | 77 (75.5%) | 210 (85.0%) | 0.034 |
Hemoglobin (g/L) | 94.5 (79.8, 116.3) | 90.0 (74.0, 107.0) | 0.105 |
Serum albumin (g/L) | 31.0 (26.8, 35.3) | 30.0 (26.0, 35.0) | 0.293 |
Complement C3 (g/L) | 0.77 (0.65, 0.93) | 0.81 (0.66, 0.92) | 0.245 |
Complement C4 (g/L) | 0.24 (0.17, 0.29) | 0.21 (0.17, 0.26) | 0.109 |
BVAS | 14.5 (10.0, 17.3) | 15.0 (11.0, 18.0) | 0.666 |
Survival | 48 (48.9%) | 137 (60.9%) | 0.047 |
Death | 50 (51.0%) | 88 (39.1%) |
|